{"id":7684,"date":"2026-05-19T02:51:00","date_gmt":"2026-05-19T00:51:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=c7a68bef15991e1e794ca71fcaf01457"},"modified":"2026-05-19T02:51:00","modified_gmt":"2026-05-19T00:51:00","slug":"attorneys-at-hagens-berman-announce-474m-win-in-amitiza-jury-trial-against-takeda","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=7684","title":{"rendered":"Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda"},"content":{"rendered":"

\nPlaintiffs\u2019 attorneys celebrate massive antitrust win against rising pharmaceutical costs<\/i><\/p><\/a><\/a>

BOSTON--(BUSINESS WIRE)--$TAK<\/a> #antitrust<\/a>--A class-action lawsuit against Takeda Pharmaceuticals USA Inc. on behalf of direct purchasers of Amitiza and its generic equivalents<\/a> ended today when a jury returned a verdict finding the pharma giant liable for $474.89 million in damages, according to attorneys at Hagens Berman.<\/p>

\nAnnounced damages are pre-trebling, a statutory requirement under U.S. federal antitrust law in which a court must multiply financial damages suffered by three as a punitive deterrent against anticompetitive behavior. This brings the total award to direct purchasers to $1.4 billion. The end payer class and retailer plaintiffs were awarded separate damages.<\/p>

\nThe five-week trial regarding the drug to treat irritable bowel syndrome and chronic constipation began April 13, 2026. The lawsuit accused brand drug sellers Takeda and Sucampo Pharmaceuticals Inc. of paying Par Pharmaceutical Inc. to delay the launch of its generic Amitiza product by up to seven years when settling patent litigation in the fall of 2014. This delay allegedly resulted in hundreds of millions of dollars in overcharges to the proposed class.<\/p>

\nAttorneys representing the plaintiff class included Thomas M. Sobol (lead trial counsel), Erin C. Burns, Kristen A. Johnson, Jessica R. MacAuley, Laura Hayes, Rebekah Glickman-Simon and Daniel Polonsky of Hagens Berman. Trial paralegals included Riya Jha and Valeria Alvarez. Attorneys described the deal between Takeda and Par in closing arguments on May 14, 2026, as a pay-for-delay scheme that unlawfully boxed out competition, highlighting that Takeda and its partner Sucampo sold about $1 billion worth of Amitiza in the years following the deal.<\/p>

\n\u201cThe jury spent five weeks listening to incredibly detailed testimony about patent litigation, FDA regulation and pharmacoeconomics, and they fundamentally understood that paying a competitor to stay out the market harms competition and harms the American healthcare system,\u201d Johnson said of the trial results.<\/p>

\nAbout the Amitiza Lawsuit Against Takeda<\/b><\/p>

\nAccording to the complaint, the alleged reverse payment took the form of Takeda\u2019s promise not to launch a competing authorized generic (AG) version of Amitiza when Par came to market. This no-AG agreement is allegedly manifest through the royalty payment structure in the settlement, which makes it economically irrational for Takeda to launch its own generic product when Par is allowed to do so.<\/p>

\nAccording to the complaint, in exchange for Takeda\u2019s agreement not to bring a competing market to public, Par agreed to drop its patent challenge, forego launching at-risk, and delay coming to market for five and a half years. The Supreme Court forbids such large and unjustified reverse payments.<\/p>

\nDefendants allegedly attempted to conceal their unlawful agreement through an allegedly superficial reservation in the settlement agreement that Takeda may launch its own authorized generic (AG) product.<\/p>

\nFind out more about the antitrust class-action lawsuit against Takeda regarding Amitiza.<\/a><\/p>

\nAbout Hagens Berman<\/b><\/a><\/p>

\nHagens Berman is a global plaintiffs\u2019 rights complex litigation law firm with a tenacious drive for achieving real results for those harmed by corporate negligence and fraud. Since its founding in 1993, the firm\u2019s determination has earned it numerous national accolades, awards and titles of \u201cMost Feared Plaintiff\u2019s Firm,\u201d MVPs and Trailblazers of class-action law. More about the law firm and its successes can be found at hbsslaw.com<\/a>. Follow the firm for updates and news at @ClassActionLaw<\/a>.<\/p> Contacts<\/b>

\nMedia Contact<\/b>Ash Klann\nHagens Berman\npr@hbsslaw.com<\/a>206-623-9363<\/p>","protected":false},"excerpt":{"rendered":"

Plaintiffs\u2019 attorneys celebrate massive antitrust win against rising pharmaceutical costsBOSTON–(BUSINESS WIRE)–$TAK #antitrust–A class-action lawsuit against Takeda Pharmaceuticals USA Inc. on behalf of direct purchasers of Amitiza and its generic…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7684","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7684"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7684\/revisions"}],"predecessor-version":[{"id":7685,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/7684\/revisions\/7685"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}